Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post ho...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Voso, Maria Teresa, Larson, Richard A., Jones, Dan, Marcucci, Guido, Prior, Thomas, Krauter, Jürgen, Heuser, Michael, Lavorgna, Serena, Nomdedeu, Josep, Geyer, Susan M., Walker, Alison, Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo M., Jansen, Joop H., Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Schlenk, Richard F., Ganser, Arnold, Amadori, Sergio, Cheng, Yuan, Chen, YinMiao, Pallaud, Celine, Du, Ling, Piciocchi, Alfonso, Ehninger, Gerhard, Byrd, John, Thiede, Christian, Döhner, Konstanze, Stone, Richard M., Döhner, Hartmut, Bloomfield, Clara D., Lo-Coco, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556122/
https://ncbi.nlm.nih.gov/pubmed/33049054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados